Outcomes by IPSS-R in lenalidomide-treated patients with IPSS low-/Int-1-risk MDSWith del(5q) in MDS-003 and MDS-004: A retrospective analysis

被引：3
|
作者：
Sekeres, M. [1 ]
Swern, A. [2 ]
Fenaux, P. [3 ]
Greenberg, P. [4 ]
Sanz, G. [5 ]
Bennett, J. [6 ]
Dreyfus, F. [7 ]
Cazzola, M. [8 ,9 ]
List, A. [10 ]
Garcia-Manero, G. [11 ]
Li, J. Shiansong [2 ]
Sugrue, M. [12 ]
机构：
[1] Cleveland Clin, Taussig Canc Inst, Leukemia Program, Cleveland, OH 44106 USA
[2] Celgene Corp, Biostat, Summit, NJ USA
[3] Avicenne Hosp, Dept Clin Hematol, Bobigny, France
[4] Stanford Univ, Div Hematol, Stanford, CA 94305 USA
[5] Hosp Univ & Politecn La Fe Valencia, Dept Hematol, Valencia, Spain
[6] Univ Rochester, Div Hematopathol & Hematol Oncol, Med Ctr, Rochester, NY 14627 USA
[7] Univ Paris, Hop Cochin, Dept Hematol, F-75252 Paris, France
[8] Fdn IRCCS Policlin San Matteo, Dept Hematol Oncol, Pavia, Italy
[9] Univ Pavia, I-27100 Pavia, Italy
[10] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Hematol Malignancies, Tampa, FL 33612 USA
[11] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[12] Celgene Corp, Med Affairs, Summit, NJ USA
来源：
LEUKEMIA RESEARCH | 2013年 / 37卷
关键词：
D O I：
10.1016/S0145-2126(13)70152-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-104
引用
收藏
页码：S69 / S70
页数：2
相关论文
共 50 条
  • [21] Lenalidomide Treatment Is Not Related to AML Progression Risk but Is Associated with a Survival Benefit in RBC Transfusion-Dependent Patients with IPSS Low- or Int-1-Risk MDS with del5q: Results From a Comparative Study
    Kuendgen, Andrea
    Lauseker, Michael
    List, Alan F.
    Fenaux, Pierre
    Giagounidis, Aristoteles
    Brandenburg, Nancy
    Backstrom, Jay
    Glasmacher, Axel
    Hasford, Joerg
    Germing, Ulrich
    BLOOD, 2011, 118 (21) : 58 - 59
  • [22] UPDATE ON SAFETY AND LONG-TERM OUTCOMES IN LENALIDOMIDE (LEN)-TREATED PATIENTS WITH RED BLOOD CELL (RBC) TRANSFUSION-DEPENDENT LOW-/INT-1-RISK MYELODYSPLASTIC SYNDROMES (MDS) AND DEL(5Q)
    Hellstrom-Lindberg, E.
    Giagounidis, A.
    Selleslag, D.
    Mittelman, M.
    Muus, P.
    Benettaib, B.
    Fu, T.
    Fenaux, P.
    HAEMATOLOGICA, 2012, 97 : 358 - 359
  • [23] Clonal activation of Akt in low-risk MDS patients with del(5q) treated with lenalidomide
    Follo, M. Y.
    Mongiorgi, S.
    Clissa, C.
    Stoyanova, M.
    Paolini, S.
    Quaranta, M.
    Martinelli, G.
    Manzoli, L.
    Cocco, C.
    Finelli, C.
    LEUKEMIA RESEARCH, 2013, 37 : S28 - S28
  • [24] p53 Mutant Independently Impacts Risk: Analysis of Deletion 5q, Lower-Risk Myelodysplastic Syndromes (MDS) Patients Treated with Lenalidomide (LEN) in the MDS-004 Study
    Saft, Leonie
    Li, Jack Shiansong
    Greenberg, Peter L.
    Sekeres, Mikkael A.
    Sanz, Guillermo F.
    Dreyfus, Francois
    Fenaux, Pierre
    Swern, Arlene S.
    Sugrue, Mary M.
    Hellstrom-Lindberg, Eva
    BLOOD, 2014, 124 (21)
  • [25] Azacitidine (AZA) After Failure of Lenalidomide (LEN) in Low/Int-1 Risk MDS with Del 5q
    Bally, Cecile
    Itzykson, Raphael
    Gruson, Berangere
    Francois, Dreyfus
    Siguret, Virginie
    Taksin, Anne-Laure
    de Renzis, Benoit
    Legros, Laurence
    Thomas, Xavier
    Bouabdallah, Krimo
    Chaibi, Pascal
    Kelaidi, Charikleia
    Fenaux, Pierre
    Ades, Lionel
    BLOOD, 2011, 118 (21) : 1200 - 1201
  • [26] CLINICAL BENEFIT AMONG LENALIDOMIDE (LEN)-TREATED PATIENTS (PTS) WITH RBC TRANSFUSION-DEPENDENT (RBC-TD) LOW-/INT-1-RISK MYELODYSPLASTIC SYNDROMES (MDS) WITHOUT DEL(5Q)
    Garcia-Manero, G.
    Almeida, A.
    Fenaux, P.
    Gattermann, N.
    Giagounidis, A.
    Goldberg, S.
    Ozawa, K.
    Weaver, J.
    Sugrue, M. M.
    Santini, V.
    HAEMATOLOGICA, 2016, 101 : 72 - 73
  • [27] Clinical benefit among lenalidomide (LEN)-treated patients (pts) with RBC transfusion-dependent (RBC-TD) low-/int-1-risk myelodysplastic syndromes (MDS) without del(5q).
    Garcia-Manero, Guillermo
    Almeida, Antonio Medina
    Fenaux, Pierre
    Gattermann, Norbert
    Giagounidis, Aristoteles
    Goldberg, Stuart
    Ozawa, Keiya
    Weaver, Jerry
    Sugrue, Mary M.
    Santini, Valeria
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [28] Effect of Lenalidomide (LEN) Exposure on AML-Free Survival and Overall Survival in LEN-Treated Patients (Pts) with IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS) with Del(5q)
    Sekeres, Mikkael A.
    Swern, Arlene S.
    List, Alan F.
    Fenaux, Pierre
    Sogrue, Mary M.
    BLOOD, 2015, 126 (23)
  • [29] Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)
    Pierre Fenaux
    Aristoteles Giagounidis
    Dominik Selleslag
    Odile Beyne-Rauzy
    Moshe Mittelman
    Petra Muus
    Stephen D. Nimer
    Eva Hellström-Lindberg
    Bayard L. Powell
    Agnes Guerci-Bresler
    Mikkael A. Sekeres
    H. Joachim Deeg
    Consuelo del Cañizo
    Peter L. Greenberg
    Jamile M. Shammo
    Barry Skikne
    Xujie Yu
    Alan F. List
    Journal of Hematology & Oncology, 10
  • [30] Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)
    Fenaux, Pierre
    Giagounidis, Aristoteles
    Selleslag, Dominik
    Beyne-Rauzy, Odile
    Mittelman, Moshe
    Muus, Petra
    Nimer, Stephen D.
    Hellstrom-Lindberg, Eva
    Powell, Bayard L.
    Guerci-Bresler, Agnes
    Sekeres, Mikkael A.
    Deeg, H. Joachim
    del Canizo, Consuelo
    Greenberg, Peter L.
    Shammo, Jamile M.
    Skikne, Barry
    Yu, Xujie
    List, Alan F.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2017, 10
12345